MENU
+Compare
ABEO
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$5.78
Change
-$0.04 (-0.69%)
Capitalization
251.26M

ABEO Abeona Therapeutics Forecast, Technical & Fundamental Analysis

a developer of pharmaceutical products

Industry Biotechnology
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for ABEO with price predictions
Feb 21, 2025

ABEO saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for ABEO moved out of overbought territory on February 19, 2025. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 53 similar instances where the indicator exited the overbought zone. In of the 53 cases the stock moved lower. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 20, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ABEO as a result. In of 100 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABEO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

ABEO broke above its upper Bollinger Band on February 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ABEO's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ABEO just turned positive on January 28, 2025. Looking at past instances where ABEO's MACD turned positive, the stock continued to rise in of 37 cases over the following month. The odds of a continued upward trend are .

ABEO moved above its 50-day moving average on February 12, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for ABEO crossed bullishly above the 50-day moving average on February 12, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ABEO advanced for three days, in of 244 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 139 cases where ABEO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ABEO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.488) is normal, around the industry mean (12.481). P/E Ratio (0.000) is within average values for comparable stocks, (84.446). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). ABEO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (30.303) is also within normal values, averaging (251.221).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
ABEO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

ABEO is expected to report earnings to fall 44.44% to -34 cents per share on March 24

Abeona Therapeutics ABEO Stock Earnings Reports
Q4'24
Est.
$-0.35
Q3'24
Missed
by $0.24
Q2'24
Beat
by $0.07
Q1'24
Missed
by $0.65
Q4'23
Missed
by $0.12
The last earnings report on November 14 showed earnings per share of -62 cents, missing the estimate of -39 cents. With 168.59K shares outstanding, the current market capitalization sits at 251.26M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Generic
Address
6555 Carnegie Avenue
Phone
+1 646 813-4701
Employees
84
Web
https://www.abeonatherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OIGIX33.13-0.38
-1.13%
Invesco Oppenheimer International Gr R6
AIGIX19.96-0.30
-1.48%
Alger International Opportunities I
MNNYX63.57-1.10
-1.70%
Victory Munder Multi-Cap Y
EKJYX13.10-0.42
-3.11%
Allspring Premier Large Co Gr Inst
PAHSX7.09-0.24
-3.27%
PGIM Jennison NextGeneration Glb Opps A

ABEO and Stocks

Correlation & Price change

A.I.dvisor tells us that ABEO and AXON have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ABEO and AXON's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABEO
1D Price
Change %
ABEO100%
-0.69%
AXON - ABEO
31%
Poorly correlated
-5.28%
SCPH - ABEO
29%
Poorly correlated
-3.27%
XNCR - ABEO
29%
Poorly correlated
-0.32%
AMRN - ABEO
28%
Poorly correlated
-0.82%
RZLT - ABEO
28%
Poorly correlated
-2.16%
More